Opioids Flashcards

1
Q

medical uses

A

pain → anti-nociceptive
blocks afferent transmission in the spinal cord/brainstem + PAG

safe and effective when used appropriately

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

PAG

A

periaqueductal gray
dorsal midbrain (tegmentum)
modulation of pain transmission - sets thresholds

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

opioid epidemic

A

skyrocketing opioid prescriptions preceded opioid-related death epidemic

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

opioids + sedatives

A

lethal mix
polypharmacy - depressant drugs
synergism of respiratory response
depression of critical brain functions (respiration) = low (or no) resp rate = no O2 flow

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

prevention of overdose

A

Naloxone
Methadone
First Responders

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

naloxone

A

opioid receptor antagonist

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

methadone

A

mu partial agonist → competes with other opioids for binding
delayed kinetics; reduces symptoms of withdrawal → used clinically to help recovery
NMDA receptor antagonist

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

sources of opioids

A

natural
semi-synthetic
synthetic

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

natural opioids

A

opium
contains morphine, codeine

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

semi-synthetic opioids

A

derived from opium
heroin
hydro-codone/-morphone, oxycodone
krokodil
buprenorphine, etorphine

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

synthetic opioids

A

methadone, meperidine
tramadol
fentanyl

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

composition of opium

A

narcotic (morphine [10%] + codeine [0.5%]) and non-narcotic alkaloids

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

kinetics of opium

A

morphine is 10x more potent than opium
CYP2D6 converts codeine to morphine in brain + liver

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

codeine

A

prodrug
requires metabolism to be active

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

pharmacogenomics of codeine

A

10% of caucasians have deficient CYP2D6 = codeine has no effect
2% of population has overactive CYP2D6 = morphine intoxication

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

heroin

A

semi-synthetic opioid = produced by modifying naturally-derived chemical
morphine + two acetyl groups = 10x more lipophilic
→ faster distribution to brain = rapid onset of euphoria

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

synthetic opioid sources

A

diphenylacetonitrile → methadone
cyclohexanone → tramadol
4-piperidone hydrochloride → fentanyl

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

discovery of opioid receptors

A

synthesis of naloxone → saw reversal of morphine effects

later, tracing of radiolabelled drugs to determine targets
Pert and Snyder

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Pert and Snyder

A

discovery of opioid receptors in the brain by radio-labelling
→ radioligand binding
4 classes: mu, delta, kappa, ORL-1

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

presynaptic receptors

A

modulate neurotransmitter release
dopamine, norepinephrine, GABA

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

post synaptic receptors

A

alter membrane potential

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

endogenous opioids

A

18 different peptide ligands that bind to opioid receptors
endorphins are widest class → range of functions

all contain N-terminal tyrosine residue → morphine structure mimics tyrosine

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

functions of endorphins

A

pain, emotional responses, euphoria, eating, memory, stress, seizures, and alcohol dependence

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

mu opioid receptors

A

most opioids bind mu receptors

morpheus - sleep (tranquilizing effects)
expressed in VTA, NAc, PAG, hypothalamus, LC, brainstem, pupils, GI tract
involved in reward, addiction, analgesia, euphoria, anxiolysis, respiration, blood pressure, nausea, itch, vasoconstriction, constipation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

delta opioid receptors

A

found in vas deferens tissue
expressed in neocortex, striatum, NAc, substantia nigra, olfactory bulb

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

enkephalins

A

endogenous opioids
bind delta receptors

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

kappa opioid receptors

A

ketocyclazocine → ligand specific to kappa receptor

expressed in pituitary, hypothalamus, PAG, spinal cord

bound by endorphins and dynorphins, + PCP and ketamine

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

kappa receptor → dysphoria

A

most aversive withdrawal symptoms → leads to relapse/binge
= target of potential treatments

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
29
Q

ORL 1 opioid receptor

A

expressed in limbic system and spinal cord
bound by buprenorphine

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
30
Q

contamination of drugs with fentanyl

A

fentanyl: similar appearance to rx pills (80mg oxycontin)
sold as heroin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
31
Q

fentanyl

A

use as surgical anaesthetic + analgesic
100x more potent than morphine
40-50x more potent than heroin
highly lipophilic

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
32
Q

fentanyl derivatives

A

increased affinity for mu receptors + enhanced entry into the brain = higher potency
carfentanil
3-methylfentanyl

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
33
Q

absorption

A

higher purity (rx) = safer administration → street opioids are often contaminated with adulterants (baking soda, talcum, fentanyl)

administration:
inhalation, injection, ingestion

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
34
Q

distribution

A

most are not lipophilic (heroin and fentanyl are) → do not readily cross BBB
liver, lungs, spleen, GI, brain

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
35
Q

metabolism

A

heroin → morphine in the brain
metabolized in the liver

pills → first pass metabolism = reduced bioavailability
alter route of administration (crush, heat, + inject) to get higher [ ]

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
36
Q

excretion

A

kidneys

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
37
Q

chasing the dragon

A

heat up on tin foil + inhale fumes
metal aerosolizes → metal toxicity, accumulation of metals in brain
linked to leukoencephalopathy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
38
Q

leukoencephalopathy

A

aversive effect of ‘chasing the dragon’ method of administration
destruction of white matter in CNS
brain tissue → spongiform (holes in brain)
progresses (over time) to ataxia, apathy, akathisia, to inability to move or speak

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
39
Q

injecting heroin

A

mix drug with water, dissolve with acid/heat
drawn up through cotton ball (filtration)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
40
Q

risks of injection

A

track marks
damage to blood vessels - needle, drug, injection rate, infection
uneven blood flow, thrombosis, clots
vessels collapse

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
41
Q

heroin pharmacokinetics

A

faster distribution to the brain (lipophilic) = higher potency
can be snorted
metabolized to morphine in the brain → metabolites:
3-MAM and 6-MAM

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
42
Q

6-MAM

A

6-monoacetylmorphine
metabolite of heroin - not naturally occurring, indicative of heroin use
binds mu receptor (3-MAM does not)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
43
Q

acute effects of opioids

A

brain
(medulla)
eyes
circulatory system
lungs
skin
GI
muscles

44
Q

acute effects in brain

A

brainstem chemotrigger zones in area postrema of medulla → triggers nausea, vomiting (usually develop tolerance to effects)

euphoria
impaired judgement
reduced pain

45
Q

acute effects in medulla

A

lowers blood pressure = hypotension
bronchoconstriction
itching

46
Q

acute effects in eyes

A

mu and kappa receptors in oculomotor nucleus → constricted pupils
heroin = parasympathomimetic response

47
Q

acute effects in skin and muscles

A

lowered body temp, flushed skin
muscle relaxation

48
Q

acute effects in CV and lungs

A

vasodilation, lowered blood pressure
slowed respiration

49
Q

physiological effects of opioids

A

reproduction
constipation
decreased urination
NAS

50
Q

effect on reproduction

A

reduced levels of GnRH, LH, FSH = decreased libido, impotence, amenorrhea

51
Q

constipation

A

isometric muscle contractions reduce bowel movements, secretions

52
Q

decreased urination

A

constriction of ureter and sphincters of bladder, stimulation of anti-diuretic hormone release

53
Q

neonatal abstinence syndrome

A

withdrawal
babies are irritable, vomit, diarrhea, seizures, respiratory distress

54
Q

reinforcing mechanism of opioids in NAc

A

opioid binds to receptor on GABA interneuron = inhibition
→ less GABA release → no inhibition of dopamine neuron (= disinhibition)
→ increased dopamine release

55
Q

opioid receptor origin

A

mu, delta, and kappa → separate Opr genes
expressed in multiple brain regions, spine, GI tract, etc.

ORL receptor shows structural homology

subtypes likely due to allelic variation → impacts function

56
Q

receptor peptides

A

delta = enkephalin (met and leu)
kappa = dynorphin (A and B)
mu = endorphin (β, 1, 2)

57
Q

opioid receptor signaling

A

ligand binds → triggers GPCR cascade (Gi = inhibition)
= inhibition of AC → reduced cAMP, inhibits PKA

alpha-GTP: activation of PLCβ and MAPK pathways

58
Q

βy subunits - OR signaling

A

activate GIRK3 (K+ channel) = hyperpolarization
block Ca2+ channels = reduced intracellular Ca2+ → suppress NT release

59
Q

ORs are GPCRs

A

Gi/o = inhibitory

60
Q

chronic exposure to morphine

A

G-protein coupled receptor kinase-mediated phosphorylation of opioid receptors and binding of β arrestin → desensitization

61
Q

two pathways connected to OR GPCR

A

G-protein → analgesia
β-arrestin → respiratory depression (shut off pathway)

62
Q

biased agonism

A

differential activation of signaling pathways by OR ligand
selective operation of signaling cascades

63
Q

selective activation of OR GPCR

A
  1. not all signaling is G-protein mediated → selective G-protein independent cascades depend on scaffold formation, direct physical contacts
  2. orthosteric stabilization of receptor conformations alter scaffolding
64
Q

classic opioid signaling

A

biased G-protein effects:
morphine keeps receptor phosphorylation low
other opioids produce high receptor phosphorylation → receptor internalization, increased tolerance and dependence ex. fentanyl

65
Q

non-synonymous mutations in mu opioid receptor

A

affect signaling and function
L85I and R181C are mutants that show altered patterns of internalization in presence of morphine

66
Q

descending pain pathway

A

cortex → thalamus → PAG → RVM →dorsal horn of spine
*sometimes thalamus is bypassed

67
Q

pain afferent threshold

A

set by tonic firing of GABA interneurons in RVM to dorsal horn

68
Q

mechanism of opioid-mediated analgesia

A

activation of mu opioid receptor on GABA RVM interneurons
= reduced inhibition of RVM “off” projecting cells to spinal cord
→ elevated signaling from RVM to spinal cord = ↓ afferent pain transmission into the spine

activation of muOR on RVM ‘ON’ projecting cells to the spinal cord = decreased outputs to the dorsal horn
→ + analgesic effect

69
Q

indirect role of amygdala

A

modifies pain transmission
state of mind; when in fight-or-flight, do not feel pain

70
Q

in dorsal spine horns

A

pre-synaptic muOR activation on afferent pain neurons reduces neurotransmitter release and pain transmission

71
Q

contextual memory → associative conditioning

A

hippocampal mu receptors
astrocyte mu receptors

72
Q

hippocampal mu receptors

A

disinhibition of CA1 and dentate gyrus cells via GABA interneurons

73
Q

astrocyte mu receptors

A

activation causes Glu release onto CA1 neurons

74
Q

NAc medium spiny neurons

A

express D1-like receptors + D2-like receptors
→ functions are subdivided

75
Q

D1 receptors

A

co-express dynorphin

mu receptors are usually co-expressed on D1 receptor expressing cells

76
Q

D2 receptors

A

co-express enkephalin

77
Q

metabolic tolerance

A

changes in distribution → faster breakdown = more tolerant of effects

78
Q

cellular tolerance

A

opioid receptors are down-regulated→ need higher dose for same effects
molecular uncoupling may disrupt OR signals (internalization of receptor → desensitization)

79
Q

behavioural tolerance

A

behaving sober when intoxicated

80
Q

tolerance reduces some effects

A

tolerant to: analgesia, vomiting, euphoria, respiratory depression

no tolerance to: constipation + pupil constriction

81
Q

lower tolerance in different locations

A

tolerant rats given high doses in same or different environments
higher (nearly double) mortality in different environment

82
Q

rat park experiment

A

morphine administration is influenced by psychosocial environment
isolated rats administered much more morphine

83
Q

behavioural sensitization

A

gauge psychological addiction → escalation of behavioural responses to a stimulus (drug of abuse) after drug-free period

factors: receptor density, NT levels, cell signaling deregulation

84
Q

behavioural sensitization driven by NAc inputs

A

dopamine-ergic projections from VTA and glutamatergic from PFC to the NAc

blocking D1 (antagonist) in NAc impairs sensitization

85
Q

morphine sensitization

A

elevated D1 expression in NAc shell + elevated transcription factor (ERK1/2 MAPK) activity

86
Q

AMPA/NMDA receptor antagonists

A

block the induction of sensitization
do not block expression of sensitization → if it has already been learned, the pathways are already established and it can’t be blocked

87
Q

desensitization

A

cellular tolerance

rapid; direct consequence of drug-receptor activation
depends on Ca2+ and K+ activities

sustained desensitization reduces acute effects (analgesia) but enhances intracellular signaling

88
Q

GRK phosphorylation of muOR

A

causes B-arrestin binding and reduced euphoria/analgesia

causes addicts to use higher doses for same effect = tolerance

89
Q

hyperalgesia

A

caused by desensitization
heroin tolerance: decreased latency in pain sensing

used barbadin: B-arrestin inhibitor = stops hyperalgesia

90
Q

short term opioid exposure

A

internalization of receptor; once B-arrestin is shut off, receptor is recycled and returns to membrane surface

91
Q

long term opioid exposure

A

internalization of receptor; eventual receptor degradation = permanent removal
increased levels of AC, PKC, PKA, and NMDA → hyperalgesia

92
Q

withdrawal

A

stages:
1. 6 hrs after last dose → emotional response = craving, anxiety
2. 12-14 hrs → physical symptoms = yawning, sweating, watery eyes, runny nose
3. 14-16 hrs → opposite of acute effects = dilated pupils, goose bumps, hot/cold flashes, fever, diarrhea, aching, no appetite
4. 2-5 days → weakness, depression, insomnia, elevated BP/heart rate/breathing, restlesness, hyperglycemia

93
Q

affective signs of withdrawal

A

cognitive symptoms
dysphoria, anxiety, irritability, cravings

mesolimbic system

targets for therapy, prevention of relapses

94
Q

mesolimbic system - withdrawal affective signs

A

NAc
LC

95
Q

NAc - affective withdrawal signs

A

naloxone injection = conditioned place aversion
D2-like receptor agonist injection attentuates somatic withdrawal signs

DA in NAc is decreased

96
Q

LC - affective withdrawal signs

A

LC expresses mu and kappa opioid receptors

chronic use suppresses LC activity = ↓ NE released
tolerance → up regulation of activity to normal
= removal of opioids → overactivity = NE surge:
sweating, chills, stomach cramps, emesis, diarrhea, muscle pain, runny nose/eyes

97
Q

LPGi

A

lateral paragigantocellularis in rostroventral medulla
stimulates LC via glutamatergic inputs
modulates withdrawal symptoms

98
Q

withdrawal treatment

A

anti-adrenergics: clonidine/lofexidine
synthetic opioids: buprenorphine, methadone

99
Q

clonidine or lofexidine

A

alpha2 adrenoceptor agonist
prevents NE release via pre-synaptic alpha2 autoreceptors
targets LC projections

100
Q

buprenorphine

A

for maintenance
semi synthetic partial agonist
out competes morphine, blocks heroin

101
Q

suboxone

A

4:1 buprenorphine:naloxone sublingual
[naloxone can not cross mucosal membranes]
→ if injected, effects are blocked (naloxone = antagonist)

102
Q

methadone

A

for maintenance
long half-life
NMDA receptor antagonist

103
Q

methadone kinetics

A

stable plasma concentration = does not reach ‘high’ level but doesn’t dip below into withdrawal symptoms

104
Q

opioid overdoses

A

triad:
coma = unresponsive
depressed respiration
pinpoint pupils

105
Q

naloxone

A

prevents opioid overdose
targets mu, kappa, and delta ORs
competitive antagonist
short-acting ~20-40 min

106
Q

main brainstem network

A

Pre-Botzinger complex + retro-trapezoid nucleus/parafacial respiratory group = coupled oscillator that influences motoneurons → produce breathing

107
Q

depressed respiration

A

reduced pre-Botzinger complex output
unresponsiveness
upperairway obstruction due to reduced upper airway muscle tone (genioglossus)